Veronica Salais Michaus

Ultimo post en 🇪🇸 Cómo leer un ensayo clínico para oncólogos ocupados, basado en el paper de @oncology_bg ✅El comparador era válido? ✅Quién lo paga? ✅SG o SLE? ✅Crossover? ✅El beneficio importa? ✅Se parecen a mis pacientes? ✅Qué toxicidad? + en: …independientedeoncologia.blogspot.com/2026/04/como-l…

Enriching Exchange of Latin American and Global Oncology Perspectives - Veronica Salais Michaus (@MichausSalais) @myESMO oncodaily.com/voices/veronic… #OncoDaily #Oncology #Cancer #Health #Medicine #MedX

I had the privilege of participating in a biliopancreatic tumors preceptorship at Hospital Clínic de Barcelona ⁦@MacarullaTeresa⁩ I am deeply grateful to all the faculty and speakers for their generosity in sharing their knowledge and experience ⁦@hospitalclinic⁩

@oncodaily @OncoDailyGI

Grateful for the opportunity to present a clinical case at the ESMO Preceptorship in Gastroesophageal Cancer in Colombia🇨🇴 @Betzabe100 @myESMO An enriching exchange of Latin American and global perspectives with inspiring colleagues, mentors, and friends.

New mCRC ESMO guidelines! Triplet chemo + bevacizumab → SoC regardless of sidedness in mKRAS MSS/non-BRAF pts. TRIPLETE (+ EGFR) may also have a role in selected subgroups. Updated maintenance strategies too. Let’s review & discuss 👏🏻

MMR IHC Interpretation – Super Simple Quick Algorithm 🔥 Test the 4 proteins → All present? → pMMR (good) One or more missing? → dMMR (needs attention) Then follow the exact pattern of loss: MLH1 & PMS2 lost (most common) → Check BRAF & MLH1 methylation MSH2 & MSH6 lost → Likely Lynch Only MSH6 or only PMS2 lost → Possible Lynch Weird single losses (MSH2 alone or MLH1 alone) → Not possible, recheck! Key rule: Always read MMR as pairs, not single markers! (MLH1 protects PMS2 • MSH2 protects MSH6) Saves time in daily practice. Save & share! #MVOnco #Oncology #Pathology #MedEd

🇫🇷 French Intergroup Guidelines 2026: Gastric Cancer Updated clinical practice guidelines provide a comprehensive framework for the management of gastric and gastroesophageal junction adenocarcinoma, covering diagnosis, staging, treatment strategies, and follow-up, with increasing integration of biomarker-driven approaches. @MeherAbdelghani @MichelDucreux 📎 oncodaily.com/oncolibrary/fr… #GastricCancer #GIOncology #Oncology #PrecisionOncology

🧪 NOM (W&W) in LARC 📊 Paradigm shift: surgery no longer mandatory in selected pts 🔹 cCR after TNT/immunotherapy → NOM feasible (~40%) 🔹 Organ preservation + QoL benefit 🔹 Requires strict selection + intensive follow-up 💥 De-escalation after upfront intensification 🔗 thelancet.com/journals/eclin… @OncoAlert

A 6-min overview of colorectal cancer for gastroenterologists — here we summarize the key points from the most recent guidelines (NCCN, ESMO) 👇

Rethinking How We Approach the Treatment of Gastrointestinal Cancers - Veronica Salais Michaus (@MichausSalais) oncodaily.com/voices/veronic… #Cancer #Oncology #OncoDaily #Health #Medicine #MedX

Still surreal - My first paper in Nat Rev Oncol (IF 82) ✨ Our review on metastatic gastric cancer is now live. Grateful to be part of this incredible team led by my mentor Y. @YJanjigianMD with J. Choo, V. Khachatryan, S. Lonardi, F. @FilippoPietran4 R. Sundar & @KlempnerSam

@Staufertjr 👏🏼👏🏼👏🏼👏🏼👏🏼🩷

Proud of the strong participation of the Genitourinary Tumors Unit at INCan #GU26 🇲🇽

🔥 New data in press from KC-WISE phase III trial: anbenitamab (anti-HER2 bispecific) + CT vs CT in trastuzumab-treated HER2-positive G/GEJ adenoca. 👉84% treated in 2L 👉 Benefit in PFS (7.1 m vs 2.7, HR 0.25) 👉 OS benefit (19.6 m vs 11.5 m, HR 0.29), still immature...

FDA grants traditional approval to encorafenib for metastatic colorectal cancer with a BRAF V600E mutation buff.ly/3qsjW9I On February 24, 2026, the FDA granted traditional approval to encorafenib (Braftovi) combined with cetuximab and fluorouracil-based chemotherapy for adults with BRAF V600E mutation-positive metastatic colorectal cancer. The approval was supported by the BREAKWATER trial, which showed encorafenib plus cetuximab and mFOLFOX6 nearly doubled median progression-free survival (12.8 vs. 7.1 months) and overall survival (30.3 vs. 15.1 months) compared to standard chemotherapy, upgrading its prior 2024 accelerated approval.

👵📊 NAPOLI-3 | Older pts (≥70 yrs) 1L mPDAC (n=217) 💥 NALIRIFOX vs Gem+nab-P → benefit preserved 📈 OS: 10.0 mo (≥70) vs 11.7 mo (<70) 📊 PFS: 7.3 vs 7.4 mo 🛡️ No increase in toxicity in older pts 👉 Age alone should not preclude 1L triplet in fit patients? @OncoAlert 🔗 doi.org/10.1016/j.esmo…

🧬 MSS mCRC & ICI: liver matters Retrospective study (n=132): • 70% liver M1 at ICI start • No liver M1: better outcomes  📈 CB : 46% vs 16%  ⏳ mPFS: 2.5 vs 2.1 mo (HR 1.68)  🧬 mOS: 11.5 vs 6.2 mo (HR 2.03) ➡️ Liver M1 = negative prognostic factor for ICI in MSS mCRC. 🔗 doi.org/10.1158/2767-9… @OncoAlert

Attending ASCO GI for the first time has been truly emotional and deeply inspiring ✨📚 Being surrounded by a friends and a community fully committed to gastrointestinal cancers, highlighting why this field matters so much ⁦@ASCO⁩ #GI26

Review Neoadjuvant and adjuvant therapy for biliary tract cancer: Advances and limitations Wilbur et al. #LiverX shorturl.at/pyeJh

Top 10 #ASCOGI26 trials to look out for 🔥🧬 1️⃣ HERIZON-GEA-01 Phase III zanidatamab based combinations in HER2 positive gastric and GEJ adenocarcinoma. Strong first line OS and PFS signal. 2️⃣ ILUSTRO Zolbetuximab plus chemotherapy with or without immunotherapy in CLDN18.2 positive HER2 negative gastric and GEJ cancer. 3️⃣ LUCERNA Zolbetuximab combined with chemotherapy and PD-1 blockade in CLDN18.2 positive PD-L1 positive gastric cancer. 4️⃣ ACCENT Narmafotinib with gemcitabine and nab-paclitaxel in metastatic pancreatic ductal adenocarcinoma. Updated phase II efficacy and safety. 5️⃣ PT886-101 Spevatamig plus standard chemotherapy as first line treatment in metastatic pancreatic cancer. Early phase signal generating study. 6️⃣ ASP3082-001 First in human KRAS G12D degrader program in advanced solid tumors including pancreatic cancer. 7️⃣ TIGeR-PaC Targeted intra-arterial delivery of chemotherapy for locally advanced and metastatic pancreatic cancer. 8️⃣ CIRCULATE-GI ctDNA guided adjuvant and surveillance strategy across colorectal and other GI malignancies. 9️⃣ CHALLENGE-CRC Structured exercise intervention trial evaluating disease free survival and quality of life in colorectal cancer survivors. 🔟 DISCO-NET Next generation somatostatin receptor imaging trial comparing novel PET tracers in neuroendocrine tumors. @ASCO @ConquerCancerFd @OncoAlert @Larvol